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Abstract
The T cell immunoglobulin mucin 3 (Tim-3) receptor is highly expressed on HIV-1-specific T cells, rendering them partially
‘‘exhausted’’ and unable to contribute to the effective immune mediated control of viral replication. To elucidate novel
mechanisms contributing to the HTLV-1 neurological complex and its classic neurological presentation called HAM/TSP
(HTLV-1 associated myelopathy/tropical spastic paraparesis), we investigated the expression of the Tim-3 receptor on CD8
+
T cells from a cohort of HTLV-1 seropositive asymptomatic and symptomatic patients. Patients diagnosed with HAM/TSP
down-regulated Tim-3 expression on both CD8
+ and CD4
+ T cells compared to asymptomatic patients and HTLV-1
seronegative controls. HTLV-1 Tax-specific, HLA-A*02 restricted CD8
+ T cells among HAM/TSP individuals expressed
markedly lower levels of Tim-3. We observed Tax expressing cells in both Tim-3
+ and Tim-3
2 fractions. Taken together, these
data indicate that there is a systematic downregulation of Tim-3 levels on T cells in HTLV-1 infection, sustaining a profoundly
highly active population of potentially pathogenic T cells that may allow for the development of HTLV-1 complications.
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Introduction
The vast majority of HTLV-1-infected individuals with low and
stable HTLV-1 proviral load levels are clinically asymptomatic for
life[1].However,1–3%ofsubjectsdevelopprogressiveneurological
complications related to HTLV-1 infection, classically denominated
as HTLV-1 associated myelopathy/tropical spastic paraparesis
(HAM/TSP) [2,3,4]. The infection can also lead to a debilitating
malignancy, known as HTLV-1 associated adult T cell leukemia
(ATL) in approximately 2–5% of infected individuals [4,5,6,7].
The immune response, and in particular the cellular immune
response, plays an important role in the control of HTLV-1
infection [8,9,10,11,12]. In vitro studies further demonstrate that
CD8
+ T cell responses are able to directly lyse HTLV-1-infected
CD4
+ T cells [9,11,13]. In patients with HAM/TSP, CD8
+ T cells
are capable of producing multi-cytokine responses and are able to
release cytotoxic molecules [14,15]. Recent studies have selected
out patients with HLA-A*02 and HLA-Cw08 genes as being
associated with lower HTLV-1 proviral load and a reduced risk of
progression to HAM/TSP [16,17].
While these data support an important protective role for the
CD8
+ T cell immune response with the potential for viral control,
other studies suggest that HTLV-1-specific CD8
+ T cells may
paradoxically contribute to the neuromuscular immunopathology
through autoimmune mechanisms, leading to the clinical manifes-
tation of HAM/TSP [18]. Furthermore, patients with HAM/TSP
also present with high numbers of HTLV-1 Tax-specific CD8+ T
cells in the cerebrospinal fluid [15,19,20,21,22] that are thought to
play a immunopathogenic role, either by release of neurotoxic
cytokines, such as TNF-a and IFN-c [23,24], or by direct
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CD8
+ T cells in the control or pathogenesis of HTLV-1 disease
progression remain unclear. Further knowledge of the mechanisms
leading to T cell induced immunopathology in HTLV-1 infection
will be important in determiningsuccessful immune-based therapies
and provide insights for effective vaccine designs.
During chronic viral infections, virus-specific CD8
+ T cells
undergo an altered pattern of differentiation and can become
exhausted [25,26]. CD8
+ T cell exhaustion is a transcriptionally
altered state of T cell differentiation distinct from functional
effector or memory CD8
+ T cells [27]. CD8
+ T cell exhaustion
leads to profound T cell dysfunction and the inability of the T cells
to control retroviral replication [28,29,30]. Conversely, downreg-
ulation of exhaustion markers could lead to a highly functional
population of T cells. T cell immunoglobulin and mucin domain-
containing protein 3 (Tim-3), is upregulated on CD8
+ T cells
during chronic viral infections [29,30,31,32,33,34,35,36]. Pro-
grammed death receptor-1 (PD-1) is also known as another
immune exhaustion biomarker expressed in chronic viral infec-
tions [28,37,38,39,40,41,42,43]. High levels of PD-1 and Tim-3
on virus-specific T cells have been shown to lead to poor
proliferative capacity and, in some cases, ineffective Th1 cytokine
production [29,39,44]. A sustained downregulation of these
receptors would lead to an exacerbated constitutively active T
cell population. The phenotypic profile of immune exhaustion
markers on T cells is unknown in seropositive HTLV-1
individuals. In this study, we show for the first time that HTLV-
1 associated complications may be related to the highly responsive
inflammatory Tax-specific T cells in HTLV-1-infected individuals.
These results support the idea that HTLV-1 infection induces
mechanisms resulting in a limited T cell exhaustion profile, leading
potentially to neuro-immunopathology and disease complications.
Materials and Methods
Ethics Statement
The research involving human participants reported in this
study was approved by the institutional review board of the
University of Sao Paulo (IRB #0855/08) Sao Paulo, Brazil.
Informed consent was obtained for all subjects. All clinical
investigation were conducted according to the principles expressed
in the Declaration of Helsinki (http://www.wma.net/en/
30publications/10policies/b3/index.html).
Humans Subjects
Patients were serially recruited in the HTLV-1 Outpatient
Clinic at the University of Sao Paulo, Brazil in two stages with
written informed consent approved by the University of Sao
Paulo’s Institutional Review Board (#0855/08). The diagnosis of
HAM/TSP based on criteria outlined by the WHO [45] (Table 1).
The majority of the patients were female (63%) with a median age
of 48 (IQR: 22–66) years. We enrolled age and sex matched
healthy uninfected volunteers without clinical and laboratory
evidence of HTLV-1-associated disease, from the same demo-
graphics as the infected subjects. All HTLV -1 seropositive subjects
tested negative for Hepatitis B, Hepatitis C, and HIV infections.
No other inflammatory diseases or disorders were present in any of
Table 1. Patients description.
ID
Number Gender Age
Clinical
Presentation PBMC
HLA-
A*02
(years) (cps/1000) Status
237 M 39 asymptomatic 20 pos
410 F 43 asymptomatic 14 pos
411 F 47 asymptomatic 84 pos
405 F 22 asymptomatic 15 pos
403 F 53 asymptomatic 604 pos
240 F N/A asymptomatic 0 pos
425 M 29 asymptomatic 43
416 M 48 asymptomatic 140 pos
221 M N/A asymptomatic 9 pos
424 M 46 asymptomatic 106
418 M 66 asymptomatic ,1
419 F 33 asymptomatic 72
421 M 54 asymptomatic 23
423 F 42 asymptomatic 72
218 F 46 HAM/TSP 2 pos
402 F 50 HAM/TSP 152 pos
224 F 57 HAM/TSP 1923 pos
412 F 53 HAM/TSP 117 pos
312 F N/A HAM/TSP 161 pos
413 F 61 HAM/TSP 1510 pos
420 M 64 HAM/TSP 12
422 F 64 HAM/TSP ND
HD1 N/A N/A Healthy
HD2 F 46 Healthy
HD3 F 39 Healthy
HD4 F 29 Healthy
HD5 F 60 Healthy
HD6 M 37 Healthy
HD7 F 45 Healthy
ND=not detected, N/A =not available.
doi:10.1371/journal.pntd.0001030.t001
Author Summary
The retrovirus, Human T lymphotropic virus type 1 (HTLV-1)
infects 10–20 million people worldwide. The majority of
infected individuals are asymptomatic; however, approxi-
mately 3% develop the debilitating neurological disease,
HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP). There is also currently no cure, vaccine or
effective therapy for HTLV-1 infection. The precise role of
CD8+ killer T cells in the control or contribution of HTLV-1
disease progression remains unclear. The T-cell immuno-
globulin mucin domain-containing (Tim) proteins are type 1
transmembrane proteins. Three human Tim proteins (Tim-1,
-3, and -4) exist and display markedly diverse expression
patterns and functions. Tim-3 is upregulated on CD8
+ T cells
during chronic viral infections leading to a population of
poorlyfunctioningT cells.Weinvestigated theexpressionof
Tim-3 on T cells from patients with asymptomatic and
symptomatic HTLV-1 infection and compared this with
HTLV-1 uninfected donors. Patients diagnosed with HAM/
TSP down-regulated Tim-3 expression on T cells when
compared to asymptomatic patients and uninfected
controls.Ourstudyprovidesevidenceofanovelmechanism
for the persistent inflammation observed in HTLV-1 infected
patients with neurological deficits and significantly advanc-
es our understanding of how the Tim-3 pathway functions.
T Cell Exhaustion Markers in HTLV-1 Infection
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PLUS (Amersham Pharmacia Biotech, Uppsala, Sweden) gradient
centrifugation, and peripheral-blood mononuclear cells (PBMC)
were isolated and cyropreserved in fetal bovine serum (FBS)
containing 10% DMSO in liquid nitrogen.
Pentamers, Peptides and Cytokines
Conjugated Pentamers were obtained commercially from
Proimmune (Oxford, UK). The HLA-A*02 restricted HTLV-1
Tax (LLFGYPVYV) and CMV (NLVPMVATV) peptides were
obtained from New England Peptide (Gardner, MA). In some
experiments rIL-2 [80 IU/ml] (Roche Diagnostics, Mannheim,
Germany) and rIL-15 [50 ng/ml] (R&D Systems, Minneapolis,
MN) were used during in vitro culture studies.
Flow Cytometry Assessment
Cryopreserved PBMC were rapidly thawed in warm RPMI
1640 with 10% FBS, washed in FACS buffer (PBS, with 0.5%
bovine serum albumin, 2 mM EDTA (Sigma-Aldrich, St. Louis,
MO)). For staining, 5610
5 cells were incubated with conjugated
antibodies against Tim-3 (R&D Systems, Minneapolis, MN), PD-1
(Biolegend, San Diego, CA), CD4, CD8, CD3 (all from BD
Biosciences, San Jose, CA) for 30 min on ice. In some
experiments, PMBC were then fixed and permeabilized prior to
staining with conjugated anti-Tax (clone Lt-4) antibodies [46] or a
control labeled IgG. Fluorescence minus one (FMO) samples were
prepared for each fluorochrome to facilitate gating as well as
conjugated isotype control antibodies. Anti-mouse IgG-coated
beads were stained with each fluorochrome separately and used
for software-based compensation. Analysis was performed using a
FACSCanto instrument (BD Biosciences) and at least 100,000
events were collected and analyzed with FlowJo software
(TreeStar, Ashland, OR).
To define pentamer positive cells: staining was initially
performed immediately after thawing with biotin-labeled HLA-
A2 Tax or CMV epitope specific pentamer fluorotags followed a
secondary staining step with fluorophore conjugated antibodies
against CD8 (BD), Tim-3 (R&D Systems), PD-1 (Biolegend) and
CD3 (BD), and with labeled streptavidin. Cells were washed twice
with PBS containing 1% FBS, then fixed in 2% paraformaldehyde
and run on a customized BD FACSCanto within 12 hours.
Viral Load Assessment
HTLV-1 proviral DNA was extracted from PBMC using a
commercial kit (Qiagen GmbH, Hilden Germany) and according
to the manufacturer’s instructions. The extracted DNA was used
as a template to amplify a fragment of 158 bp from the viral tax
region using previously published primers[47]. The SYBR green
real-time PCR assay was carried out in 25 ml PCR mixture
containing 106Tris (pH 8.3; Invitrogen, Brazil), 1.5 mM MgCl2,
0.2 mM of each primer, 0.2 mM of each dNTPs, SYBR Green
(18.75 Units/r6n; Cambrex Bio Science, Rockland, ME) and 1
unit of platinum Taq polymerase (Invitrogen, Brazil). The
amplification was performed in the Bio-Rad iCycler iQ system
using an initial denaturation step at 95uC for 2 minutes, followed
by 50 cycles of 95uC for 30 seconds, 57uC for 30 seconds and 72uC
for 30 seconds. The human housekeeping b globin gene primers
GH20 and PC04[48] were used as an internal control calibrator.
For each run, standard curves for the value of HTLV-1 tax were
generated from MT-2 cells of log10 dilutions (from 10
5 to 10
0
copies). The threshold cycle for each clinical sample was calculated
by defining the point at which the fluorescence exceeded a
threshold limit. Each sample was assayed in duplicate and the
mean of the two values was considered as the copy number of the
sample. The amount of HTLV-1 proviral load was calculated as
follows: copy number of HTLV-1 (tax) per 1,000 cells = (copy
number of HTLV-1 tax)/(copy number of b globin/2) 61,000
cells. The method could detect 1 copy per 10
3 PBMC.
Elispot Assays
MAIPS4510 Elispot plates (Millipore, Danvers, MA) were
coated with anti-IFN-c (10 mg/ml) (Mabtech, Nacka Strand,
Sweden) in PBS, 50 ml/well, either overnight at 4uC or for one
hour at room temperature. After three washes with PBS, PBMC
(1610
5 cells/well) and the appropriate antigens were added (Tax
peptide and CMV peptide), with a final volume of 200 ml/well.
Plates were incubated at 37uCi n5 %C O 2 for 16–20 hours. After
washing with phosphate-buffered saline (PBS) plus 0.1% Tween 20
(PBST), biotinylated anti-IFN-c 1 mg/ml) (Mabtech), antibodies
were added to the appropriate wells in PBS 0.1% tween 1% BSA
(PBSTB) for 30 minutes at room temperature. Plates were washed
again three times with PBST, and alkaline phosphatase-conjugat-
ed streptavidin (Jackson Immunoresearch, West Grove, PA) was
added (50 ml of 1:1,000 dilution in PBSTB) and incubated for
30 min at room temperature. Plates were washed in PBSTB,
soaked for 1 hour in PBSTB and incubated with blue substrate
(Vector Labs, Burlingame, CA) until spots were clearly visible,
then rinsed with tap water. When plates were dry, spots were
counted using an automated ELISPOT reader.
Statistical Analysis
Statistical analysis was performed by using GraphPad Prism
statistical software (GraphPad Software, San Diego, CA). Non-
parametric statistical tests were used. The Mann-Whitney U was
used for comparison tests and the Spearman rank test were used
for correlation analyses.
Results
Subjects
Peripheral venous blood was drawn from 22 HTLV-1
seropositive patients and 7 HTLV-1 seronegative matched
donors, all screened for the presence of HLA-A*02 alleles, and
peripheral blood mononuclear cells (PBMC) were extracted and
cryopreserved.
Tim-3 and PD-1 Expression on CD8+ and CD4+ T Cells in
Patients with HTLV-1 Infection
Tim-3 and PD-1 are two cellular molecules expressed on T cells
implicated in immune exhaustion. We evaluated the expression
and co-expression of Tim-3 and PD-1 on T cells derived from
HTLV-1 seropositive (both asymptomatic carriers and patients
with the diagnosis of HAM/TSP) and seronegative controls to
determine whether they were modulated in HTLV-1 infection.
We observed a significant decrease in the frequency of Tim-3
+ PD-
1
2 expressing CD8
+ and CD4
+ T cells among HTLV-1
seropositive subjects (CD8
+: median 8.01%, IQR 5.42–10.50;
CD4
+: median 4.3%, IQR 3.50–5.99) compared to HTLV-1
seronegative controls (CD8
+ median 15.10%, IQR 10.50–17.60;
CD4
+: median 6.84%, IQR 5.74–7.85) (Figure 1A and B). Patients
with HAM/TSP (red circles) had significantly lower levels of Tim-
3
+ PD-1
2 expressing CD8
+ (p=0.002) and CD4
+ (p=0.004) T
cells compared to healthy uninfected controls (open circles). In
contrast, the frequency of Tim-3
2 PD1
+ T cells trended to an
increase in subjects with HTLV-1 infection (CD8
+: median
18.80%, IQR 10.42–24.90; CD4
+: median 20.70%, IQR 13.6–
25.35) compared to healthy uninfected controls (CD8
+: median
9.22%, IQR 8.97–15.50; CD4
+: median 13.60%, IQR 12.7–18.6)
T Cell Exhaustion Markers in HTLV-1 Infection
www.plosntds.org 3 April 2011 | Volume 5 | Issue 4 | e1030Figure 1. Tim-3 expression on T cells in HTLV-1 infection. Graphs show the frequencies of co-expression of Tim-3 and PD-1 on (A) CD8+ (left),
and (B) CD4+ (right), T cells as assessed by multiparametric flow cytometry from PBMCs derived 18 HTLV-1 seropositive (12 asymptomatic and 6 with
diagnosis of HAM/TSP) infected subjects and 7 HTLV-1 seronegative healthy uninfected donors from our initial recruitment. Statistically significant
differences are reported as p,0.05.
doi:10.1371/journal.pntd.0001030.g001
Figure 2. Tim-3 expression on HTLV-1-specific CD8+ T cells in HTLV-1 infection. PBMC from HLA-A*02+ chronically HTLV-1 infected
individuals were stained with matched HLA pentamers presenting CMV and HTLV-1 epitopes, and with an anti-Tim-3 antibody. Shown are
representative flow cytometry data from one HTLV-1-infected person using HLA-A*02 pentamers presenting the (A) HTLV-I-Tax 11–19 epitope and,
(B) CMV-pp65 epitope ‘NLVPMVATV’. (C, D) Plots show co-expression of Tim-3 (upper panel) and PD-1 (lower panel) with the respective HLA-A*02
pentamers (Tax (left) and CMVpp65 (right)) from the gated CD8+ T population depicted in Fig 2 A, B. The percentages of cells in the upper left and
right quadrants of the flow plots demonstrated in Figure 2C, D reflect only the percentage of pentamer expressing cells. The compiled expression
data of the frequency of Tax (E) and CMVpp65 (F) pentamer cells on either Tim-3+ or Tim-3- and PD-1+ or PD-1- CD8+ T cells from 8 subjects are
shown in Figure 2 E and F. Statistical analyses comparing pooled responses were performed using the Mann-Whitney test.
doi:10.1371/journal.pntd.0001030.g002
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and PD-1, and no differences were observed between uninfected
subjects and those with HTLV-1 asymptomatic infection or
HAM/TSP patients. Using linear regression analysis we observed
no association between the frequency of Tim-3 or PD-1 expression
on CD8
+ T cells in HTLV-1 infected subjects and proviral load.
(p=0.68; r=0.1043; or p=0.89; r=20.03202, respectively).
Distribution of Tim-3 Expression on HTLV-1-Specific T
Cells
HLA- A*02 positive HTLV-1-infected patients have high
amounts of circulating CD8
+ T cells specific for an immunodomi-
nant HLA- A*02 -restricted epitope, HTLV-1 Tax 11–19
[20,49,50]. In HAM/TSP patients, these HTLV-1’s Tax-specific
CD8
+Tcellscorrelatewith HTLV-1proviralload[23].Amongthis
cohort, we identified 15 HLA-A2 positive subjects (asymptomatic
carriers, n=9 and HAM/TSP, n=6; Table 1), and evaluated the
Tim-3 and PD-1 receptor expression on Tax-specific CD8
+ T cells.
Eight patients had Tax-specific CD8
+ T cells (median 2.45%, IQR
1.11–5.31) as determined by specific pentamers. Among these
patients we also observed HLA-A*02 -restricted CMVpp65 CD8+
T cells(median2.49%,IQR1.87–11.37).Interestingly,Tim-3 levels
were dramatically reduced on CD8
+ Tax 11–19-specific T cells
(median 24.77%, IQR 15.2–39.54) compared to the expression of
PD-1 (median 48.06%, IQR 36.81–65) (Figure 2A,C and E). We
also evaluated Tim-3 expression on HLA- A*02 CMV specific T
cells and found a similar pattern of expression with Tim-3 levels
reduced on CD8
+ CMV-specific T cells (median 27.62%, IQR
21.48–43.19) compared to PD-1 (median 47.70%, IQR 40.45–
51.16) (Figure 2B,D and F).
Relationship between the Functionality of Tax
11-19-Specific CD8
+ T Cells and Tim-3 Levels
To determine whether there was an association with Tim-3 or
PD-1 levels on Tax 11–19-specific CD8
+ T cells and their
functionality, we evaluated the production of IFN-c in response to
the HLA-A*02-restricted Tax 11–19 immuno-dominant epitope
and in comparison, the CMVpp65 epitope by an ELISPOT assay
derived from PBMCs derived from 8 HLA- A*02 restricted infected
individuals with Tax 11–19- and CMVpp65 specific CD8
+ T cells
(Figure 3). We saw no correlation between IFN-c secretion and
global PD-1 or Tim-3 expression on either the CD4
+ or CD8
+ T
cells, irrespective of disease status (data not shown). The frequency
of PD-1 expression on Tax-specific or CMV-specific CD8
+ T cells
Figure 3. Association of Tax specific CD8+ T cells with effector responses. The graphs show the association between the frequency of Tim-3
(A) and PD-1 (B) expression on HLA-A*02 restricted Tax11-19 or CMV pp65 specific CD8+ T cells with the number of IFN-c secreting cells (SFU/10
6)i n
response to Tax 11–19 peptide or the CMV pp65 epitope. The Spearman rank test was used for correlation analyses.
doi:10.1371/journal.pntd.0001030.g003
T Cell Exhaustion Markers in HTLV-1 Infection
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P=0.7520 and r=0.2245; P=0.594, respectively) (Figure 3B).
However, we observed a statistically significant inverse correlation
between the frequency of Tim-3 on both Tax-specific as well as
CMV-specific CD8
+ T cells and the amount of IFN-c secreted
(r=20.8982; P=0.0046; r=0.9710; P=0.0028; Figure 3A).
Co-Expression of Tim-3 and Tax on T Cells in HTLV-1
Infected Cells
Tax expression marks HTLV-1 viral replication in both CD4
+
and CD8
+ infected T cells. We aimed to determine whether the
downregulation of Tim-3 we had observed was occurring only
among infected cells, or in bystander cells as well. We therefore co-
stained for Tax and Tim-3 expression on T cells from HTLV-1
infected subjects. We also stained for PD-1 expression as a control.
The culture of PBMC overnight did not alter Tim-3 or PD-1
expression levels on the HTLV-1-infected T cells (data not shown).
We observed that Tax was expressed on PBMC from some
subjects following 24 hours of culture and was detected on both
Tim-3
+ as well as Tim-3
2 CD4
+ T cells (Figure 4A). Similarly,
Tax was present on both PD-1
+ and PD-1
2 T cells. We further
identified a unique subset of Tax expressing CD4+ T cells that
were Tim-3
hi and lacked PD-1 in most of the subjects expressing
Tax (Fig. 4A). No difference in the pattern of co-expression
between HTLV-1 seropositive asymptomatic patients and those
diagnosed with HAM/TSP was observed.
Elevated Tim-3 Expression by IL-2 and IL-15 Stimulated T
Cells from HTLV-1 Infected Subjects
An increase in Tim-3 levels on T cells would potentially lead to a
downregulation of T cell functionality. We therefore tested several
gamma-chain associated cytokine mediators that could potentially
modulate Tim-3 expression. We observed that IL-2, and especially
IL-15, led to a prominent increase in the frequency of Tim-3 levels,
specifically on the CD8+ T cell population after only 12 hours in
culture (Figure 4B,C). No change in the levels of PD-1 expression
were observed on both CD8
+ and CD4
+ T cells (Figure 4B,C).
Discussion
CD8
+ T cell dysfunction and/or exhaustion are common
features of many chronic viral infections, including HIV-1 and
HCV infections [29,30,31,32,33,34,35,36]. The mechanisms of
T cell dysfunction are complex, but are in part mediated by a
distinct set of inhibitory receptors [27,51]. A high, and
sustained, expression of Tim-3 and PD-1, have emerged as
hallmarks of T cell exhaustion in human viral infections, and
blockade of these pathways can reinvigorate immune responses
during persisting viral infections [29,30,33,34,36]. In this study,
we report that CD8
+ and CD4
+ T cells in HTLV-1 infection
express lower levels of Tim-3, and this was more pronounced in
patients with HAM/TSP. Phenotypically, we observed that Tax
HTLV-1-specific, HLA-A*02 -restricted CD8
+ T cells consis-
tently retain a lower frequency of Tim-3. We propose that this
low expression of Tim-3 on HTLV-1 Tax-specific T cells may
lead to a persistent and deleterious effector T cell pool leading
to more inflammation.
The pattern of expression of PD-1 in HTLV-1 infection has
recently been shown to be elevated on T cells in HTLV-1 carriers
and also on CMV and EBV specific T cells in asymptomatic
carriers compared to healthy controls [52]. This opposing
relationship of PD-1 and Tim-3 expression on T cells in patients
with HTLV-1 infection suggests that the downregulation of Tim-3
expression potentially leads to more vigorous T cell activity in the
HTLV-1-infected individual, whereas PD-1 may not fully reflect T
cell dysfunction, but rather an activated status of the T cell
response to infection. Indeed the association between the
frequency of Tim-3 and PD-1 levels with IFN-c secretion in
response to either Tax or CMVpp65 epitopes show remarkably
different correlations. In a study by Petrovas and colleagues, it was
apparent that PD-1 expressing T cells are able to secrete cytokines
in response to viral peptides [39]. Our data suggests that PD-1 and
Tim-3 on antigen specific CD8
+ T cells are functionally different,
and this may reflect a distinct stage of differentiation. PD-1
appears to mark early T-cell activation and exhaustion, while
Tim-3 represents a more terminal stage of impairment.
The positive association between the frequency of HTLV-1’s
Tax-specific CD8
+ T cells and HTLV-1’s Tax mRNA load and
proviral load is well documented [8,53,54]. Studies evaluating the
phenotype of CD8
+ T cells in HTLV-1 infection have been largely
limited to characterizing the expression of T cell maturation and
differentiation markers (CD28, CD45RO) [14]. Our data suggest
that downregulation of Tim-3, rather than PD-1, marks global and
Tax-specific CD8
+ T cells, which are hyperfunctional. This
contrasts with HIV-1 and HCV infections, where the expression
of Tim-3 is increased, leading to a population of CD8
+ T cells that
are rendered dysfunctional both in terms of proliferative capacity
and cytokine release as well as release of cytolytic granules [29,36].
Surface receptors known to regulate T cell function like CD244
and PD-1 have been shown to be upregulated either directly due
to Tax or indirectly due to the cytokine milieu [52,55]. We
postulate that either direct HTLV-1 viral components led to a
downregulation of Tim-3, or as yet to be defined cytokine(s),
suppress Tim-3 expression. In several human and murine studies,
the manifestation of autoimmune diseases such as multiple
sclerosis, have been attributed as a result of downregulated Tim-
3 expression on T cells [56].
It still remains unclear how HTLV-1 infection sustains low levels
ofTim-3onT cellsininfected patientsand whetherthisisa causeor
a consequence of disease progression. Multilayered mechanisms for
this regulation may be occurring in the context of HTLV-1
infection. One strategy to reduce the T cells response would be
through enhancement of the Tim-3 receptor for engagement with
its cognate ligand. This could serve as a novel strategy to dampen
the inflammatory inducing T cells. From our results, PD-1
engagement may not be as effective since both PD-1
2 and PD-1
+
cells retain the potential for CD8
+ T cell lytic function.
A novel strategy to reverse or prevent the onset of neurological
complications would be through dampening effector T cell
functions. From our results, it appears the c-chain cytokines
elicited higher levels of Tim-3 on specifically on CD8
+ T cells, and
such a strategy could be harnessed to dampen T cell function in
the HTLV-1 infected individual. Further work to understand the
mechanisms for HTLV-1 disease progression and devise strategies
to effectively prevent neurological complications will be needed.
Figure 4. Tim-3, PD-1 and Tax co-expression on T cells. (A) Plots demonstrate representative co-staining for Tax, PD-1 and Tim-3 on CD8+ and
CD4+ T cells by flow cytometry following 24 hours incubation for the induction of Tax in two representative HTLV-1 infected patients. An isotype
control was used to delineate the measurements for Tax expression. (B, C) Plots and graph depict the co-expression of Tim-3 and PD-1 by the
indicated cytokines after 12 hr in vitro culture of 1610
6 PBMC from 4 HTLV-1 infected patients. A representative donor is shown in B.
doi:10.1371/journal.pntd.0001030.g004
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model for this intervention.
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